ViroGates announces its half-year report for H1, 2023 on 17th August 2023 and will host a webcast for investors
COMPANY ANNOUNCEMENT - No. 13-2023 - 11 August 2023
BIRKERØD, DENMARK – ViroGates A/S inform that it will announce its half-year report covering 1 January 2023 – 30 June 2023 on Thursday 17th August 2023. The report will be released immediately after the Board of Directors' approval on the same day.
ViroGates will host a webinar for investors on Friday 18th August at 10:00. The meeting will be an online interactive meeting with an initial presentation of the results from the H1, 2023 report and a subsequent Q&A session.
Sign up for the webinar here.
When the report is announced, it will be available on the Investor webpage.
For further information, please contact:
ViroGates A/S:
CEO, Jakob Knudsen
Tel. (+45) 2226 1355, email: jk@virogates.com
Certified Advisor:
Västra Hamnen Corporate Finance
Per Lönn
Tel. (+46) 40 200 250, email: per.lonn@vhcorp.se
About ViroGates
ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff.
The company was founded in 2000. Headquartered in Denmark, ViroGates’ sales force covers Spain, France, and Benelux, while distributors serve other markets. ViroGates’ shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.
Disclosure regulation
Prospects about the future reflect ViroGates' current expectations for future events and results. The statements are by nature inherent in risks, uncertainties and other matters that are difficult to predict or out of control. The actual results may therefore differ from the expectations expressed.
Contacts
- Jakob Knudsen, CEO, +45 2226 1355, jk@virogates.com